Table 6.
CP (n = 13) | PL (n = 14) | |||||
---|---|---|---|---|---|---|
BL | 6 w | 12 w | BL | 6 w | 12 w | |
Body weight, kg | 59.2 ± 4.9 | 59.0 ± 5.0 | 58.8 ± 5.0 | 58.4 ± 4.5 | 58.3 ± 4.7 | 58.3 ± 4.7 |
BMI, kg/m2 | 23.9 ± 0.6 | 23.8 ± 0.8 | 23.8 ± 0.9 | 24.6 ± 1.4 | 24.6 ± 1.5 | 24.7 ± 1.4 |
Abdominal circumference, cm | 87.6 ± 4.6 | 87.2 ± 5.3 | 88.5 ± 4.3 | 85.1 ± 5.1 | 87.0 ± 4.0 | 86.2 ± 4.9 |
Percent body fat, % | 37.7 ± 5.4 | 36.5 ± 4.8 | 35.4 ± 4.1 *,† | 37.0 ± 7.0 | 36.7 ± 6.7 | 36.3 ± 7.0 |
Visceral fat index | 99.6 ± 28.8 | 100.0 ± 19.3 | 102.3 ± 20.6 | 100.4 ± 25.6 | 105.0 ± 23.6 | 100.7 ± 23.5 |
Muscle mass, kg | 37.0 ± 5.8 | 37.6 ± 5.8 | 38.1 ± 5.3 | 36.9 ± 5.8 | 37.0 ± 5.9 | 37.3 ± 6.1 |
Muscle mass percentage, % | 14.1 ± 3.4 | 14.8 ± 1.9 | 14.7 ± 1.9 | 14.6 ± 2.3 | 14.7 ± 2.4 | 14.7 ± 2.4 |
Fat free mass, kg | 24.7 ± 2.2 | 25.0 ± 1.8 | 25.1 ± 2.2 | 24.9 ± 3.0 | 25.2 ± 2.8 | 25.2 ± 2.8 |
Abbreviations: CP, capsinoids group; PL, placebo group; BL, baseline; 6 w, 6th week; 12 w, 12th week. Significantly larger change than PL in linear mixed model repeated ANOVA (* p < 0.05); significant difference between CP and PL in ANCOVA (covariate = baseline value) († p < 0.05).